NCT01810913 2026-04-17
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2/3 Recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
Ohio State University Comprehensive Cancer Center
Eastern Cooperative Oncology Group
University of Michigan Rogel Cancer Center